ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers

IMGO Imago BioSciences Inc

36.01
0.00 (0.00%)
Last Updated: 00:00:00
Delayed by 15 minutes
Share Name Share Symbol Market Type
Imago BioSciences Inc NASDAQ:IMGO NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 36.01 37.82 34.21 0 00:00:00

Merck to Buy Imago for $36 A Share, More Than Double Friday's Close

21/11/2022 12:29pm

Dow Jones News


Imago BioSciences (NASDAQ:IMGO)
Historical Stock Chart


From Jan 2022 to Jan 2025

Click Here for more Imago BioSciences Charts.

By Colin Kellaher

 

Merck & Co. on Monday said it agreed to buy clinical-stage biopharmaceutical company Imago BioSciences Inc. in a $1.35 billion cash deal that bolsters Merck's hematology portfolio.

Kenilworth, N.J., drugmaker Merck said it would pay $36 a share for Imago, more than double Friday's closing price of $17.40 for the South San Francisco, Calif., company.

Imago is a developing new medicines for the treatment of myeloproliferative neoplasms and other bone-marrow diseases. The company's lead product candidate, bomedemstat, is in multiple Phase 2 studies for the treatment of essential thrombocythemia, myelofibrosis and polycythemia vera.

Merck said it expects to complete the acquisition of Imago in the first quarter of 2023.

 

Write to Colin Kellaher at colin.kellaher@wsj.com

 

(END) Dow Jones Newswires

November 21, 2022 07:14 ET (12:14 GMT)

Copyright (c) 2022 Dow Jones & Company, Inc.

1 Year Imago BioSciences Chart

1 Year Imago BioSciences Chart

1 Month Imago BioSciences Chart

1 Month Imago BioSciences Chart